Isoxazoline compositions and use thereof in the prevention or treatment of parasite infestations in animals

• US 10,456,358 B2
• Filed: 12/19/2014
• Issued: 10/29/2019
• Est. Priority Date: 12/20/2013
• Status: Active Grant

• Current Assignee: Intervet Incorporated
• Original Assignee: Intervet Incorporated
• Inventors: Lehay, Anne, Flochlay-Sigognault, Annie
• Primary Examiner(s): Pihonak, Sarah
• Application Number:
  US15/102,414
• Publication Number:
  US 20160317439A1
• Time in Patent Office: 1,775 Days
• CPC Class Codes: A01N 25/02 containing liquids as carriers, diluents or solvents
• CPC Class Codes: A01N 43/80 five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
• CPC Class Codes: A23K 20/105 Aliphatic or alicyclic compounds
• CPC Class Codes: A23K 20/132 containing only one nitrogen as hetero atom
• CPC Class Codes: A23K 20/137 containing two hetero atoms, of which at least one is nitrogen
• CPC Class Codes: A23K 50/30 for swines
• CPC Class Codes: A23K 50/75 for poultry
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/42 Oxazoles
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/14 Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• CPC Class Codes: A61K 47/22 Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• CPC Class Codes: A61K 47/26 Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• CPC Class Codes: A61K 9/0095 Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006
• CPC Class Codes: A61K 9/08 Solutions composition of solutions A61K47/00
• CPC Class Codes: A61K 9/107 Emulsions ; Emulsion preconcentrates; Micelles composition of emulsions A61K47/00
• CPC Class Codes: A61P 33/00 Antiparasitic agents
• CPC Class Codes: A61P 33/10 Anthelmintics
• CPC Class Codes: A61P 33/14 Ectoparasiticides, e.g. scabicides

Abstract

This invention is directed to a pharmaceutical composition for drinking water administration comprising isoxazoline compounds of formula (I) and a polysorbate surfactant and diethylene glycol monoethyl ether (transcutol); and the use of the composition to treat or prevent parasite infestations of animals.

Claims

1. A method of preventing or treating parasite infestations in animals by administering to such animal in its drinking water a pharmaceutical composition consisting essentially of fluralaner or a salt or solvate thereof, and a pharmaceutically acceptable carrier consisting essentially of ethyl lactate, diethylene glycol monoethyl ether and a polysorbate surfactant.

2. The method according to claim 1 wherein the amount of fluralaner is between 1.5 mg/ml and 100 mg/ml.

3. The method according to claim 1 wherein the ratio of diethylene glycol monoethyl ether to polysorbate surfactant is <

50;

50% w/w.

4. The method according to claim 1 wherein the animals are selected from pigs and poultry.

5. The method according to claim 4 wherein the animals are laying hens.

6. The method according to claim 1 wherein the parasite infestation is a mite infestation.

7. The method according to claim 6 wherein the mite infestation is an infestation with Dermanyssus sp. or Ornithonyssus sp.

8. A medicated drinking water consisting essentially of a mixture of a pharmaceutical composition consisting essentially of fluralaner or a salt or solvate thereof, and a pharmaceutically acceptable carrier consisting essentially of ethyl lactate, diethylene glycol monoethyl ether and a polysorbate surfactant and water.

9. The medicated drinking water according to claim 8 wherein the amount of fluralaner or a salt or solvate thereof is between 0.001 and 100 mg/ml.

10. A Method for preparing medicated drinking water according to claim 8 wherein the pharmaceutical composition is diluted by injecting through a dosing pump system in a water system or by mixing with water in a medication tank.

11. The medicated drinking water of claim 8, wherein the ratio of diethylene glycol monoethyl ether to polysorbate surfactant is <

50;

50% w/w.